T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$2.57B |
| 2 |
GE Aerospace
GE
|
+$1.8B |
| 3 |
UnitedHealth
UNH
|
+$1.63B |
| 4 |
Marriott International
MAR
|
+$1.62B |
| 5 |
Apple
AAPL
|
+$1.3B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.87B |
| 2 |
JPMorgan Chase
JPM
|
+$1.64B |
| 3 |
Nike
NKE
|
+$1.59B |
| 4 |
Becton Dickinson
BDX
|
+$1.46B |
| 5 |
Alibaba
BABA
|
+$1.32B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.97% |
| 2 | Healthcare | 18.52% |
| 3 | Consumer Discretionary | 13.26% |
| 4 | Financials | 12.08% |
| 5 | Communication Services | 10.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Equitable Holdings
EQH
$14.1B
| $609M | 0.1% |
42,148,705
+2,124,765
| +5% | +$46.4M |
|
|
GLIBA
227
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
| $601M | 0.1% |
10,554,183
+129,592
| +1% | +$8.8M |
|
228
Eli Lilly
LLY
$1.09T
| $595M | 0.09% |
4,292,595
+109,970
| +3% | +$15.1M |
|
229
Assurant
AIZ
$13.9B
| $595M | 0.09% |
5,719,425
-31,515
| -0.5% | -$3.89M |
|
230
Xcel Energy
XEL
$49.1B
| $593M | 0.09% |
9,838,082
-6,261,925
| -39% | -$408M |
|
231
EOG Resources
EOG
$75.1B
| $577M | 0.09% |
16,052,779
+2,234,925
| +16% | +$145M |
|
232
Cintas
CTAS
$81.4B
| $573M | 0.09% |
13,227,688
+8,501,168
| +180% | +$555M |
|
233
Idexx Laboratories
IDXX
$45B
| $572M | 0.09% |
2,362,254
-1,275,881
| -35% | -$333M |
|
234
News Corp Class A
NWSA
$15.5B
| $569M | 0.09% |
63,411,876
+3,474,993
| +6% | +$43.8M |
|
235
Neurocrine Biosciences
NBIX
$15.9B
| $569M | 0.09% |
6,570,771
-720,526
| -10% | -$70.5M |
|
|
WUBA
236
DELISTED
58.com Inc
WUBA
| $568M | 0.09% |
11,660,482
+1,783,325
| +18% | +$102M |
|
237
Charter Communications
CHTR
$17.9B
| $563M | 0.09% |
1,290,857
+233,049
| +22% | +$114M |
|
238
AstraZeneca
AZN
$246B
| $562M | 0.09% |
6,290,756
+278,269
| +5% | +$26.2M |
|
|
COUP
239
DELISTED
Coupa Software Incorporated
COUP
| $559M | 0.09% |
3,999,478
-55,104
| -1% | -$8.53M |
|
240
Wabtec
WAB
$49.9B
| $558M | 0.09% |
11,600,649
-2,996,546
| -21% | -$206M |
|
241
ConocoPhillips
COP
$153B
| $556M | 0.09% |
18,042,569
+6,802,761
| +61% | +$346M |
|
242
Boston Scientific
BSX
$74.5B
| $553M | 0.09% |
16,942,211
+835,933
| +5% | +$32.7M |
|
243
Toro Company
TTC
$9.32B
| $551M | 0.09% |
8,469,339
-174,697
| -2% | -$13.3M |
|
244
Bristol-Myers Squibb
BMY
$130B
| $540M | 0.09% |
9,694,840
-1,468,911
| -13% | -$89.8M |
|
245
ICU Medical
ICUI
$4.48B
| $540M | 0.09% |
2,674,231
+89,469
| +3% | +$17.2M |
|
246
Costco
COST
$421B
| $534M | 0.08% |
1,871,770
+85,455
| +5% | +$25.9M |
|
247
MarketAxess Holdings
MKTX
$5.72B
| $533M | 0.08% |
1,602,390
-180,662
| -10% | -$62.9M |
|
248
Credicorp
BAP
$29.6B
| $533M | 0.08% |
3,724,730
+543,335
| +17% | +$103M |
|
249
Atmos Energy
ATO
$28.7B
| $517M | 0.08% |
5,210,553
-212,076
| -4% | -$23.3M |
|
250
Franco-Nevada
FNV
$45.5B
| $513M | 0.08% |
5,192,600
-701,336
| -12% | -$76.1M |
|
Similar funds
T. Rowe Price Associates's Q1 2020 Portfolio in Review
As of Q1 2020, T. Rowe Price Associates held 2,612 positions worth $632B, down 18% from $771B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2020 filing shows 87 new, 1,525 increased, 823 reduced and 103 closed positions. Its largest new stake was Philips: 33,363,001 shares worth $1.07B. The largest sale was Boeing, an estimated $2.87B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2020 buy was Philips: 33,363,001 shares worth $1.07B.
- T. Rowe Price Associates added most to Humana in Q1 2020, an estimated $2.57B increase.
- T. Rowe Price Associates's biggest Q1 2020 reduction was Boeing, cutting an estimated $2.87B.
- T. Rowe Price Associates fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $846M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $632B portfolio in Q1 2020.
- T. Rowe Price Associates opened 87 new positions and closed 103 in Q1 2020.
- T. Rowe Price Associates's portfolio value fell 18% quarter-over-quarter to $632B.
Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.